Table 6.

Protein subunit vaccine candidates that are currently in phase 3 of clinical development

Candidate	Dose	Schedule	Route of Administration	Phase	Developer
SARS-CoV-2 rS/Matrix M1-Adjuvant	2	Day 0 + 21	Intramuscular	Phase 3 NCT04611802 EUCTR2020-004123-16-GB NCT04583995	Novavax
CHO Cell	2–3	Day 0 + 28 or Day 0 + 28 + 56	Intramuscular	Phase 3 NCT04646590	Anhui Zhifei Longcom Biopharmaceutical and Institute of Microbiology, Chinese Academy of Sciences
VAT00002	2	Day 0 + 21	Intramuscular	Phase 3 PACTR202011523101903 NCT04904549	Sanofi Pasteur + GSK
FINLAY-FR-2 anti-SARS-CoV-2 Vaccine	2	Day 0 + 28	Intramuscular	Phase 3 RPCEC00000354	Instituto Finlay de Vacunas
EpiVacCorona	2	Day 0 + 21	Intramuscular	Phase 3 NCT04780035	Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”
CIGB-66	3	Day 0 + 14 + 28 or Day 0 + 28 + 56	Intramuscular	Phase 3 RPCEC00000359	Center for Genetic Engineering and Biotechnology (CIGB)
SCB-2019 + AS03	2	Day 0 + 21	Intramuscular	Phase-3 NCT05012787	Clover Biopharmaceuticals Inc./GSK/Dynavax
COVAX-19	2	Day 0 + 21	Intramuscular	Phase-3 IRCT20150303021315N24	Vaxine Pty Ltd./CinnaGen CO
MVC-COV1901	2	Day 0 + 28	Intramuscular	Phase-3 NCT05011526	Medigen Vaccine Biologics + Dynavax + National Institute of Allergy and Infectious Diseases (NIAID)
Recombinant SARS-Cov-2 vaccine	2	Day 0 + 28	Intramuscular	Phase-3 NCT04887207 NCT04904471	West China hospital + Sichuan University WestVac Biopharma Co., Ltd
BECOV2	2	Day 0 + 28	Intramuscular	Phase-3 CTRI/2021/08/036074	Biological E. Ltd
Nanocovax	2	Day 0 + 21	Intramuscular	Phase-3 NCT04922788	Nanogen Pharmaceutical Biotechnology
GBP510	2	Day 0 + 28	Intramuscular	Phase-3 NCT05007951	SK Bioscience Co., Ltd and CEPI
Razi Cov Pars	3	Day 0 + 21 + 51	IM and IN	Phase-3 IRCT20210206050259N3	Razi vaccine and Serum research institute